BR112017018963A2 - método para tratar anemia por deficiência de ferro - Google Patents

método para tratar anemia por deficiência de ferro

Info

Publication number
BR112017018963A2
BR112017018963A2 BR112017018963A BR112017018963A BR112017018963A2 BR 112017018963 A2 BR112017018963 A2 BR 112017018963A2 BR 112017018963 A BR112017018963 A BR 112017018963A BR 112017018963 A BR112017018963 A BR 112017018963A BR 112017018963 A2 BR112017018963 A2 BR 112017018963A2
Authority
BR
Brazil
Prior art keywords
deficiency anemia
iron deficiency
iron
patients
colitis
Prior art date
Application number
BR112017018963A
Other languages
English (en)
Inventor
Poradosu Enrique
Bentsur Ron
David SHEMESH Shay
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of BR112017018963A2 publication Critical patent/BR112017018963A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02—Iron compounds

Abstract

são descritos no presente documento métodos para tratar pacientes com anemia por deficiência de ferro (ida), que compreendem administrar citrato férrico a tais pacientes. em determinados aspectos, os pacientes tratados para anemia por deficiência de ferro têm um distúrbio gastrointestinal, tal como doença inflamatória intestinal, síndrome inflamatória intestinal, doença de crohn, colite microscópica (tal como colite colagenosa ou linfocítica) ou colite quimicamente induzida (por exemplo, colite induzida por nsaid (fármaco anti-inflamatório não esteroide)). em determinados aspectos, os pacientes tratados para anemia por deficiência de ferro têm perda de sangue associada a parto, a menstruação ou a infecção. em alguns aspectos, os pacientes tratados para anemia por deficiência de ferro têm ingestão alimentar insuficiente de ferro e/ou absorção insuficiente de ferro.
BR112017018963A 2015-03-04 2016-03-03 método para tratar anemia por deficiência de ferro BR112017018963A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127963P 2015-03-04 2015-03-04
PCT/US2016/020575 WO2016141124A1 (en) 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia

Publications (1)

Publication Number Publication Date
BR112017018963A2 true BR112017018963A2 (pt) 2018-05-15

Family

ID=56848619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018963A BR112017018963A2 (pt) 2015-03-04 2016-03-03 método para tratar anemia por deficiência de ferro

Country Status (15)

Country Link
US (2) US20180071243A1 (pt)
EP (1) EP3265077A4 (pt)
JP (2) JP2018507260A (pt)
KR (1) KR20170123664A (pt)
CN (1) CN107530310A (pt)
AU (1) AU2016226250B2 (pt)
BR (1) BR112017018963A2 (pt)
CA (1) CA2978073A1 (pt)
EA (1) EA201791960A1 (pt)
HK (2) HK1246649A1 (pt)
IL (1) IL254125A0 (pt)
MX (1) MX2017011169A (pt)
SG (1) SG11201707120PA (pt)
TW (2) TW202302083A (pt)
WO (1) WO2016141124A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
EP3685831A4 (en) 2017-09-19 2021-06-16 Japan Tobacco Inc. USE OF FERRIC CITRATE IN THE PREVENTION AND / OR TREATMENT OF FERRIPRIVE ANEMIA IN A PATIENT WITH HYPERMENORRHEA AND / OR A PATIENT WITH A GYNECOLOGICAL DISEASE ASSOCIATED WITH HYPERMENORRHEA
FR3075601A1 (fr) * 2017-12-21 2019-06-28 Clarisse Le Court Complements alimentaires et leur utilisation sur les menstruations
WO2020247935A1 (en) * 2019-06-07 2020-12-10 Arizona Board Of Regents On Behalf Of Arizona State University Body fluid iron level panel analyzer
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
WO2023047424A1 (en) * 2022-04-29 2023-03-30 West Bengal Chemical Industries Limited Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
WO2005067970A1 (ja) * 2004-01-14 2005-07-28 Gekkeikan Sake Co., Ltd. 鉄補給剤及びその利用
CA3050453C (en) * 2005-08-18 2021-07-27 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
WO2012097155A1 (en) * 2011-01-14 2012-07-19 Chiasma Inc. Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
JP2015535209A (ja) * 2012-06-21 2015-12-10 ケリク バイオファーマシューティカルス， インコーポレーテッド 慢性腎臓病患者の治療におけるクエン酸第二鉄の使用

Also Published As

Publication number Publication date
JP2021091686A (ja) 2021-06-17
SG11201707120PA (en) 2017-09-28
US20180071243A1 (en) 2018-03-15
TWI812580B (zh) 2023-08-21
US20240075006A1 (en) 2024-03-07
JP2018507260A (ja) 2018-03-15
KR20170123664A (ko) 2017-11-08
AU2016226250A1 (en) 2017-09-28
EP3265077A1 (en) 2018-01-10
EA201791960A1 (ru) 2018-01-31
MX2017011169A (es) 2017-11-09
TW201639558A (zh) 2016-11-16
IL254125A0 (en) 2017-10-31
TW202302083A (zh) 2023-01-16
CA2978073A1 (en) 2016-09-09
AU2016226250B2 (en) 2021-05-27
HK1246649A1 (zh) 2018-09-14
CN107530310A (zh) 2018-01-02
EP3265077A4 (en) 2018-10-24
WO2016141124A1 (en) 2016-09-09
HK1248589A1 (zh) 2018-10-19

Similar Documents

Publication Publication Date Title
BR112017018963A2 (pt) método para tratar anemia por deficiência de ferro
BR112017024929A2 (pt) conjugados de oligonucleotídeo-peptídeo
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
BR112015022197A2 (pt) tratamento de cataplexia
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
MX2021004558A (es) Polimeros de union a protones para administracion oral.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112018013833A2 (pt) métodos de administração de hepcidina
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
BR112018014467A2 (pt) tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112018012237A2 (pt) conjugados oligonucleotídeos-peptídeos
NZ712540A (en) Phenyl derivative having s1p2 antagonistic activity
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MY194135A (en) Treatment and diagnosis of inflammatory disorders
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements